Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference
Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - - First ...
Yahoo Finance8mon
Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s ...
Vigil presents data on oral small molecule program including VG-3927
Vigil Neuroscience (VIGL) presented data highlighting its oral small molecule program, including its lead clinical candidate VG-3927, in two ...
Hosted on MSN2mon
Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial
VG-3927 is a small molecule TREM2 agonist designed to enhance protective microglial responses to aggregated amyloid and tau proteins implicated in AD. It aims to modulate microglia without ...
Vigil says FDA removed partial hold on Alzheimer’s candidate
In June, Sanofi (SNY) agreed to obtain the right of first negotiation to exclusively license the company’s small molecule ...
Finanznachrichten23d
Vigil Neuroscience, Inc.: Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates
As the first and only, Phase 2-ready oral small molecule TREM2 agonist, VG-3927 has the potential to provide a novel, next-generation therapy for Alzheimer's disease. Additionally, with the upcoming ...
Business Insider4d
Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference
“Today’s two presentations highlight the unique potential of VG-3927 as an orally bioavailable, highly potent and CNS penetrant small molecule TREM2 agonist and provide the complete dataset ...